Rapport’s novel oral drug posts Phase II bipolar win
Rapport Therapeutics’ Phase II bipolar mania study has met its primary endpoint, as it hopes to compete on the market…
Central Nervous System
-
-
Arrowhead’s Alzheimer’s disease drug reduces tau in Phase I/IIa trial
Arrowhead Pharmaceuticals’ investigational RNA interference (RNAi) therapy being developed for Alzheimer’s disease has been shown to reduce tau in a…
-
Schizophrenia research grapples with trial design hurdles in hunt for new treatments
Placebo response in acute schizophrenia trials has been rising for decades. At the same time, the observed treatment benefit is…
-
Alzheimer’s disease market expected to reach $14.7bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 20.0% from $2.4…
-
Parkinson’s disease market expected to reach $7.2bn across the 7MM by 2033
The Parkinson’s disease (PD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and…
-
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss
Acadia Pharmaceuticals has deemed the results of its Phase II study evaluating its Alzheimer’s disease psychosis (ADP) therapy as “Phase…
-
J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar win
Johnson & Johnson’s (J&J’s) $14.6bn acquisition of Intra-Cellular Therapies is continuing to reap rewards after a Phase III trial of…
-
Axoltis’ Phase II ALS trial fails; company points to exploratory endpoints
Axoltis Pharma is undertaking additional analysis of its Phase II amyotrophic lateral sclerosis (ALS) trial after it failed to meet…
-
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
AbbVie’s preventative migraine therapy, Qulipta (atogepant), has netted a successful late-stage readout in menstrual migraine, potentially poising the drug for…
-
Biohaven’s epilepsy drug hit with FDA clinical hold
The US Food and Drug Administration (FDA) has placed a partial clinical hold on the pivotal trials evaluating Biohaven’s epilepsy…
